[1] GBD
2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and
territories,1990—2016:a systematic analysis for the global burden of disease study
2016[J]. Lancet,2018,392(10152):1015-1035.
[2] HANKEY
G J. Stroke[J]. Lancet,2017,389(10069):641-654.
[3] BANERJEE
C,CHIMOWITZ M I. Stroke caused by atherosclerosis of
the major intracranial arteries[J]. Circ Res,2017,120(3):502-513.
[4] SUH
D C,KIM J K,CHOI J W,et al. Intracranial stenting of severe symptomatic intracranial
stenosis:results of 100 consecutive patients[J]. AJNR
Am J Neuroradiol,2008,29(4):781-785.
[5] DERDEYN
C P,CHIMOWITZ M I,LYNN M J,et al. Aggressive medical treatment with or without stenting in
high-risk patients with intracranial artery stenosis(SAMMPRIS):the final results of a randomised trial[J]. Lancet,2014,383(9914):333-341.
[6] GAO
P,WANG T,WANG D M,et al. Effect of stenting plus medical therapy vs. medical therapy
alone on risk of stroke and death in patients with symptomatic intracranial
stenosis:the CASSISS randomized clinical trial[J]. JAMA,2022,328(6):534-542.
[7] PENG
G G,ZHANG J Y,JIA B X,et al. Submaximal primary angioplasty for symptomatic intracranial
atherosclerosis:peri-procedural complications and
long-term outcomes[J]. Neuroradiology,2019,61(1):97-102.
[8] PICARD
F,DOUCET S,ASGAR A W.
Contemporary use of drug-coated balloons in coronary artery disease:where are we now?[J]. Arch Cardiovasc Dis,2017,110(4):259-272.
[9] JIM
M H,FUNG R C,YIU K H.
Angiographic result of sirolimus-eluting balloon in de novo small coronary
artery lesion(ARSENAL)[J/OL].
Int J Cardiol,2016,222:992-994[2023-02-11]. https://doi.org/10.1016/j. ijcard.2016.08.133.
[10] GRUBER
P,BRAUN C,KAHLES T,et al. Percutaneous transluminal angioplasty using the novel
drug-coated balloon catheter SeQuent Please NEO for the treatment of
symptomatic intracranial severe stenosis:feasibility
and safety study[J]. J Neurointerv Surg,2019,11(7):719-722.
[11] GBD
2015 Neurological Disorders Collaborator Group. Global,regional,and national burden of neurological disorders during 1990—2015:a systematic analysis for the global
burden of disease study 2015[J]. Lancet Neurol,2017,16(11):877-897.
[12] NGUYEN
T N,ZAIDAT O O,GUPTA R,et al. Balloon angioplasty for intracranial atherosclerotic disease:periprocedural risks and short-term outcomes in a multicenter
study[J]. Stroke,2011,42(1):107-111.
[13] TOMYCZ
L,BANSAL N K,LOCKNEY T,et al. Primary balloon angioplasty for symptomatic,high-grade intracranial stenosis[J/OL]. Surg Neurol Int,2013,4:18[2023-02-11].
https://doi.org/10.4103/2152-7806.107542.
[14] REMONDA
L,DIEPERS M,BERBERAT J,et al. Drug-coated balloon treatment in symptomatic intracranial
high grade stenosis:a retrospective study of 33
patients[J]. Clin Neuroradiol,2021,31(1):45-49.
[15] TANG
Y,LI T X,LIU W B,et al. Comparison of drug-coated balloon with conventional balloon
for angioplasty in symptomatic intracranial atherosclerotic stenosis[J/OL]. J Neurointerv
Surg,2023,15(e3):e369-e374[2023-02-11].
https://doi.org/10.1136/jnis-2022-019685.
[16] HAN
J,ZHANG J,ZHANG X,et al. Drug-coated balloons for the treatment of symptomatic
intracranial atherosclerosis:initial experience and
follow-up outcome[J]. J Neurointerv Surg,2019,11(6):569-573.
[17] WANG
Y,MA Y,GAO P,et al. Primary angioplasty without stenting for symptomatic,high-grade intracranial stenosis with poor circulation[J]. AJNR Am J
Neuroradiol,2018,39(8):1487-1492.
[18] DERDEYN
C P,FIORELLA D,LYNN M J,et al. Nonprocedural symptomatic infarction and in-stent restenosis
after intracranial angioplasty and stenting in the SAMMPRIS trial(stenting and aggressive medical management for the prevention of
recurrent stroke in intracranial stenosis)[J]. Stroke,2017,48(6):1501-1506.
[19] MATTSSON
E,CLOWES A W. Current concepts in restenosis following
balloon angioplasty[J]. Trends Cardiovasc Med,1995,5(5):200-204.
[20] RITTGER
H,BRACHMANN J,SINHA A M,et al. A randomized,multicenter,single-blinded trial comparing paclitaxel-coated balloon angioplasty
with plain balloon angioplasty in drug-eluting stent restenosis:the PEPCAD-DES study[J]. J Am Coll Cardiol,2012,59(15):1377-1382.
[21] BUERKE
M,GUCKENBIEHL M,SCHWERTZ H,et al. Intramural delivery of sirolimus prevents vascular remodeling
following balloon injury[J]. Biochim Biophys Acta,2007,1774(1):5-15.
[22] OBERHOFF
M,KUNERT W,HERDEG C,et al. Inhibition of smooth muscle cell proliferation after local
drug delivery of the antimitotic drug paclitaxel using a porous balloon
catheter[J]. Basic Res Cardiol,2001,96(3):275-282.
|